- Research shows that 78% of AMD patients do not seek treatment until their visual acuity is irreversibly damaged.
- Contrast sensitivity & dark adaptation exams may aid physicians in detecting subclinical age-related macular degeneration (AMD).
- Heru is the only platform with both exams, establishing a market-leading AMD portfolio.
Miami, FL (September 14, 2022) – Today, Heru announced the launch of dark adaptation, the newest modality added to its wearable health and wellness platform’s one-of-a-kind vision screening line-up. This launch cements Heru’s position as a market leader with its AMD portfolio.
Dark adaptation measures the eye’s ability to adjust from light to dark environments. Impaired dark adaptation may be one of the earliest indicators of AMD, which is the leading cause of vision loss and accounts for 8.7% of visual impairment worldwide. Early detection of AMD is key to preserving visual function and research indicates that 78% of patients do not seek treatment until it is too late. Heru’s AMD portfolio leverages contrast sensitivity & dark adaptation, which studies have shown may aid physicians in the detection of AMD-related changes up to three years before drusen are visible, allowing for earlier intervention and management of the disease.
“We are incredibly pleased to announce the release of dark adaptation further advancing our platform and delivering on our commitment to establish a comprehensive wearable AMD portfolio,” said Mohamed Abou Shousha, MD, PhD, CEO, and founder of Heru. With this release, Heru can confidently say we are leading the way in vision and now AMD, transforming how clinicians are able to evaluate retinal function. With the introduction of each new vision exam, Heru’s proprietary technology continues to better serve patients by aiding in the detection of several sight-threatening conditions while creating unique revenue streams to support practice growth.”
Age-related macular degeneration is four times more prevalent than glaucoma, impacting 1 in 8 adults over the age of 60. For patients over 50, performing visual fields, contrast sensitivity, and dark adaptation testing should become a regular part of their annual comprehensive eye exam.
“Multifunctional devices such as Heru’s are the future of vision care,” said Barry Eiden, OD, FAAO, founder, North Suburban Vision Consultants. “Dark adaptation testing with the Heru platform is something we have been excited about adopting in our practice. With Heru, we are better equipped to detect dark adaptation impairment which studies have shown to be an early indicator of AMD. The fact that the test is an add-on to a device already in our office is a major value point, and we are excited for the additional capabilities to enhance patient care and move the industry forward.”
Compared to legacy devices, Heru’s dark adaptation exam is simple, non-invasive, and takes as little as 4.5 minutes for a rapid exam, or 20 minutes for an extended exam. Dark adaptation is billable to insurance with a national reimbursement average of $58.83 and is co-billable with visual fields, OCT, fundus imaging, and/or office visits. Dark adaptation has multiple supported ICD-10 codes and may generate additional practice revenue from auxiliary testing, plus nutraceutical and optical sales.
“Dark adaptation may enable physicians to monitor AMD progression more effectively at regular intervals and identify fast progressors. More frequent visits and proactive treatment should become the standard of care and may result in improved clinical outcomes and patient compliance,” added Gregory Caldwell, OD, FAAO, co-founder, Johnstown Family Vision. “Heru’s extensive suite of available testing modalities has filled a major gap in vision screening. I am excited to see what the company does next.”
Heru Inc. (www.seeheru.com) is a medical software company focused on the development of next-generation diagnostic solutions leveraging commercially available AR/VR head-mounted displays. The company pioneered the first multi-modal wearable solution, which has revolutionized healthcare by introducing several diagnostic modalities in a single platform. Heru is leveraging its award-winning platform to build a comprehensive diagnostic solution that is strongly correlated to the current standard of care and exceeds traditional standards of care in usability, cost, size, and portability. Future development includes therapeutic applications for personalized augmented vision correction.
In May 2021, Heru announced a $30 million Series A funding round, led by global investment firm D1 Capital Partners with participation from SoftBank’s SB Opportunity Fund and existing investors.
Heru was born out of the University of Miami’s Bascom Palmer Eye Institute. In December 2020, Heru announced a seed round led by Fred Drasner, Maurice R. Ferré, MD, Frederic H. Moll, MD, and a consortium of investors with extensive experience developing, launching, and scaling cutting-edge medical technologies.
Chief Marketing Officer